Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12091420 SARS-COV2 main protease inhibitors

Patent 12091420 was granted and assigned to Gilead Sciences on September, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Gilead Sciences

Current Assignee

Gilead Sciences

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

120914200

Patent Inventor Names

Eda Y. Canales0

Kevin X. Rodriguez0

Joshua J. Van Veldhuizen0

Weng K. Chang0

Jason K. Perry0

Gregory F. Chin0

Michael R. Mish0

Stephen E. Ammann0

...

Date of Patent

September 17, 2024

Patent Application Number

183761590

Date Filed

October 3, 2023

Patent Citations

‌

US Patent 9453026 ACC inhibitors and uses thereof

‌

US Patent 9944655 ACC inhibitors and uses thereof

‌

US Patent 10179793 ACC inhibitors and uses thereof

‌

US Patent 10472374 ACC inhibitors and uses thereof

‌

US Patent 8969557 ACC inhibitors and uses thereof

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12091420 SARS-COV2 main protease inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API